Montis Biosciences BV has released preclinical data on its lead program, MB-0109, in support of its development to treat neuro-autoimmune indications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results